Reduce exacerbations
For patients with severe eosinophilic asthma, Nucala helps to reduce exacerbations, including those requiring hospitalisations6,10,11
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
Nucala offers proven asthma control and can help reduce OCS use for your patients with severe eosinophilic asthma1,2
This is a fictional patient for illustrative purposes
82.4% of severe asthma patients prescribed Nucala in real world practice would have been ineligible to participate in Nucala clinical trials due to the inclusion criteria.5
In contrast to traditional randomised control trials, the real world evidence REALITI-A study had broad inclusion criteria to best represent the severe asthma patients you see in your clinics.6
*The primary endpoint of the REALITI-A study is a reduction in clinically significant exacerbations. The primary endpoint was met.
REALITI-A is an ongoing 2-year study in adults aged 18 years and over. The graph reports on the 1-year interim results which may not reflect the results from the final dataset.
Nucala was generally well tolerated during the trial and safety outcomes were consistent with the outcomes from randomised controlled trials.
Nucala provides your patients with severe eosinophilic asthma long-term reduction in OCS use.7
*Includes participation in MENSA (32 weeks) or SIRIUS (24 weeks; treatment for 20 weeks) and COSMOS (52 weeks; treatment for 48 weeks) prior to inclusion in COSMEX (up to 172 weeks).
**OCS use throughout the SIRIUS (24 weeks), COSMOS (52 weeks), and COSMEX (up to 172 weeks) studies in patients with ≥ 128 weeks continuous enrolment. Patients included from SIRIUS were required to have a reduction in OCS dose by ≥ 50% compared with the patient's optimised OCS dose at randomisation in SIRIUS, during SIRIUS for those randomised to mepolizumab, and during the first 6 months of COSMOS for those randomised to placebo.8 These limitations are important when interpreting results: lack of comparator arm, differences in patient population and data collection vs. randomised control trials.9
Nucala was generally well tolerated during the trial and safety outcomes were consistent with the outcomes from randomised controlled trials.
The primary endpoint in SIRIUS, percentage reduction in daily OCS dose during Weeks 20-24 compared to the baseline dose, was met (p=0.008).
Nucala was generally well tolerated during the trial and safety outcomes were consistent with the outcomes from randomised controlled trials.
mOCS: maintenance oral corticosteroids; OCS: oral corticosteroids; RWE: real-world evidence
References:
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
June 2022 | PM-GB-MPL-WCNT-220002 (V1.0)